19 results
6-K
MREO
Mereo Biopharma Group Plc
3 Sep 19
Current report (foreign)
4:05pm
-recruitment covenants.
The foregoing summary of the Employment Agreement is qualified in its entirety by reference to the complete text
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 20
Business Update and Directorate Change
9:09am
-related lung disease, who are potentially at greater risk from COVID-19 exposure. As a result, recruitment into Mereo’s Phase 2 alpha-1 antitrypsin
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
14 Mar 22
Current report (foreign)
10:05am
enrolled. Chief Investigator – Prof. Rob Stockley IDMC –both doses deemed safe to proceed Preferential recruitment to highest dose per protocol
6-K
MREO
Mereo Biopharma Group Plc
9 May 22
Current report (foreign)
8:06am
of recruitment challenges and this change was implemented during the COVID-19 pandemic. The Company made the decision to close the study when it was determined
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
9 May 22
Current report (foreign)
8:06am
announced, the protocol allowed prioritization of enrollment to the high dose arm in the case of recruitment challenges and this change was implemented
6-K
EX-10.1
jtkdzh2d6l2hizvs
3 Sep 19
Current report (foreign)
4:05pm
6-K
8vyubrxsa0dowj
17 Sep 19
Current report (foreign)
8:06am
6-K
exng0dqn
16 Jun 20
Current report (foreign)
4:13pm
10-K
7pvou034yjb10dg79rq
27 Mar 24
Annual report
5:20pm
F-4/A
ph28 3pkt
15 Mar 19
Registration of securities (foreign) (amended)
5:08pm
F-1/A
18wacc6gn0v5aet1g4
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
20-F
mky xf3a1c5awb
29 Apr 19
Annual report (foreign)
4:59pm
F-4
sz8uggkx jjue6
25 Jan 19
Registration of securities (foreign)
12:00am
F-1/A
xdjimdfnahpddk b9
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
424B3
38e3iw
20 Mar 19
Prospectus supplement
4:58pm
- Prev
- 1
- Next